Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee
Therapies targeting the programmed cell death protein-1/programmed death-ligand 1 (PD-L1) (abbreviated as PD-(L)1) axis are a significant advancement in the treatment of many tumor types. However, many patients receiving these agents fail to respond or have an initial response followed by cancer pro...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-07-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/7/e009427.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849707340154011648 |
|---|---|
| author | Charlie Garnett-Benson Sarah Warren Anne Monette Alexandra Snyder Janis M Taube J Carl Barrett Kurt A Schalper Brian Topp |
| author_facet | Charlie Garnett-Benson Sarah Warren Anne Monette Alexandra Snyder Janis M Taube J Carl Barrett Kurt A Schalper Brian Topp |
| author_sort | Charlie Garnett-Benson |
| collection | DOAJ |
| description | Therapies targeting the programmed cell death protein-1/programmed death-ligand 1 (PD-L1) (abbreviated as PD-(L)1) axis are a significant advancement in the treatment of many tumor types. However, many patients receiving these agents fail to respond or have an initial response followed by cancer progression. For these patients, while subsequent immunotherapies that either target a different axis of immune biology or non-immune combination therapies are reasonable treatment options, the lack of predictive biomarkers to follow-on agents is impeding progress in the field. This review summarizes the current knowledge of mechanisms driving resistance to PD-(L)1 therapies, the state of biomarker development along this axis, and inherent challenges in future biomarker development for these immunotherapies. Innovation in the development and application of novel biomarkers and patient selection strategies for PD-(L)1 agents is required to accelerate the delivery of effective treatments to the patients most likely to respond. |
| format | Article |
| id | doaj-art-01ae6040ff4e401b8cab10bfcad5a0ee |
| institution | DOAJ |
| issn | 2051-1426 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-01ae6040ff4e401b8cab10bfcad5a0ee2025-08-20T03:15:57ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262024-07-0112710.1136/jitc-2024-009427Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers CommitteeCharlie Garnett-Benson0Sarah Warren1Anne Monette2Alexandra Snyder3Janis M Taube4J Carl Barrett5Kurt A Schalper6Brian Topp7Bristol Myers Squibb, Princeton, New Jersey, USA7Gilead Sciences, Seattle, WA, USALady Davis Institute for Medical Research, Montreal, Québec, CanadaGenerate Biomedicines, Somerville, Massachusetts, USA9The Department of Dermatology and The Mark Foundation Center for Advanced Imaging and Genomics at Johns Hopkins University School of Medicine, Baltimore, MD, USAPrecede Biosciences, Boston, Massachusetts, USADepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut, USAMerck and Co, Rahway, New Jersey, USATherapies targeting the programmed cell death protein-1/programmed death-ligand 1 (PD-L1) (abbreviated as PD-(L)1) axis are a significant advancement in the treatment of many tumor types. However, many patients receiving these agents fail to respond or have an initial response followed by cancer progression. For these patients, while subsequent immunotherapies that either target a different axis of immune biology or non-immune combination therapies are reasonable treatment options, the lack of predictive biomarkers to follow-on agents is impeding progress in the field. This review summarizes the current knowledge of mechanisms driving resistance to PD-(L)1 therapies, the state of biomarker development along this axis, and inherent challenges in future biomarker development for these immunotherapies. Innovation in the development and application of novel biomarkers and patient selection strategies for PD-(L)1 agents is required to accelerate the delivery of effective treatments to the patients most likely to respond.https://jitc.bmj.com/content/12/7/e009427.full |
| spellingShingle | Charlie Garnett-Benson Sarah Warren Anne Monette Alexandra Snyder Janis M Taube J Carl Barrett Kurt A Schalper Brian Topp Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee Journal for ImmunoTherapy of Cancer |
| title | Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee |
| title_full | Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee |
| title_fullStr | Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee |
| title_full_unstemmed | Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee |
| title_short | Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee |
| title_sort | biomarker development for pd l 1 axis inhibition a consensus view from the sitc biomarkers committee |
| url | https://jitc.bmj.com/content/12/7/e009427.full |
| work_keys_str_mv | AT charliegarnettbenson biomarkerdevelopmentforpdl1axisinhibitionaconsensusviewfromthesitcbiomarkerscommittee AT sarahwarren biomarkerdevelopmentforpdl1axisinhibitionaconsensusviewfromthesitcbiomarkerscommittee AT annemonette biomarkerdevelopmentforpdl1axisinhibitionaconsensusviewfromthesitcbiomarkerscommittee AT alexandrasnyder biomarkerdevelopmentforpdl1axisinhibitionaconsensusviewfromthesitcbiomarkerscommittee AT janismtaube biomarkerdevelopmentforpdl1axisinhibitionaconsensusviewfromthesitcbiomarkerscommittee AT jcarlbarrett biomarkerdevelopmentforpdl1axisinhibitionaconsensusviewfromthesitcbiomarkerscommittee AT kurtaschalper biomarkerdevelopmentforpdl1axisinhibitionaconsensusviewfromthesitcbiomarkerscommittee AT briantopp biomarkerdevelopmentforpdl1axisinhibitionaconsensusviewfromthesitcbiomarkerscommittee |